There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on TherapeuticsMD (TXMD), Heron Therapeutics (HRTX) and Immunomedics (IMMU) with bullish sentiments.
TherapeuticsMD (TXMD)
In a report issued on November 7, Ken Cacciatore from Cowen & Co. maintained a Buy rating on TherapeuticsMD, with a price target of $16. The company’s shares closed on Friday at $4.93.
According to TipRanks.com, Cacciatore is a 3-star analyst with an average return of 1.8% and a 45.8% success rate. Cacciatore covers the Healthcare sector, focusing on stocks such as Liquidia Technologies Inc, Alder Biopharmaceuticals, and Adamas Pharmaceuticals.
TherapeuticsMD has an analyst consensus of Strong Buy, with a price target consensus of $20.33, a 312.4% upside from current levels. In a report issued on October 29, Cantor Fitzgerald also reiterated a Buy rating on the stock with a $27 price target.
.
See today’s analyst top recommended stocks >>
Heron Therapeutics (HRTX)
In a report issued on November 7, Boris Peaker from Cowen & Co. maintained a Buy rating on Heron Therapeutics, with a price target of $54. The company’s shares closed on Friday at $28.35.
According to TipRanks.com, Peaker is a 4-star analyst with an average return of 7.1% and a 42.6% success rate. Peaker covers the Healthcare sector, focusing on stocks such as Corvus Pharmaceuticals Inc, Stemline Therapeutics Inc, and Mersana Therapeutics Inc.
Heron Therapeutics has an analyst consensus of Strong Buy, with a price target consensus of $52.25, which is an 84.3% upside from current levels. In a report issued on October 30, Cantor Fitzgerald also reiterated a Buy rating on the stock with a $50 price target.
.
Immunomedics (IMMU)
Cowen & Co. analyst Phil Nadeau maintained a Buy rating on Immunomedics on November 7 and set a price target of $30. The company’s shares closed on Friday at $21.47.
According to TipRanks.com, Nadeau is a 4-star analyst with an average return of 7.7% and a 49.6% success rate. Nadeau covers the Healthcare sector, focusing on stocks such as Rhythm Pharmaceuticals Inc, Rocket Pharmaceuticals Inc, and Allogene Therapeutics Inc.
Immunomedics has an analyst consensus of Strong Buy, with a price target consensus of $37.38, a 74.1% upside from current levels. In a report issued on November 5, Morgan Stanley also initiated coverage with a Buy rating on the stock with a $38 price target.
.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
